LMAT LEMAITRE VASCULAR INC
FY2025 10-K
LEMAITRE VASCULAR INC (LMAT) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: global medical devices and human tissue cryopreservation services focused on treating peripheral vascular, end-stage renal, and cardiovascular diseases
- • New product emphasis: launch of PhasTIPP Powered Phlebectomy System in US (H1 2024) and marketing of Artegraft biologic graft in EU after April 2025 CE mark approval
Management Discussion & Analysis
- • Revenue $249.6M in 2025, up 14% YoY (+$29.7M from $219.9M in 2024) with highest growth in EMEA (+22%, +$13.2M)
- • Gross margin 71.5% in 2025 vs 68.6% in 2024, up 290bps; driven by Employee Retention Credit, manufacturing efficiencies, and price increases
Risk Factors
- • Regulatory risk: ASC 606 revenue recognition standard requires judgment in estimating sales returns, impacting reported revenue and allowances
- • Macroeconomic threat: $9.1 million inventory purchase commitments expose business to supply cost fluctuations through 2026
Financial SummaryXBRL
Revenue
$250M
Net Income
$58M
Gross Margin
71.5%
Operating Margin
27.2%
Net Margin
23.1%
ROE
14.7%
Total Assets
$616M
EPS (Diluted)
$2.52
Operating Cash Flow
$81M
Source: XBRL data from LEMAITRE VASCULAR INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on LEMAITRE VASCULAR INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.